olanzapine: the legal and safety record

Track one: the DOJ case, with a court record

In January 2009, Eli Lilly pleaded guilty to misdemeanor misbranding and agreed to pay $1.415 billion over the off-label promotion of Zyprexa — specifically, marketing it as a dementia treatment for elderly patients between 1999 and 2001, a use the FDA never approved [1].

The criminal fine — $515 million — was described by the Department of Justice as the largest ever imposed on an individual corporation in any US prosecution at the time. And the plea it attached to was a misdemeanor. That pairing is the honest summary of how pharmaceutical criminal resolutions work: enormous fines, modest charges, no individual defendants — worth understanding as a system fact rather than treating either half as the whole story.

Track two: the injury settlements, without one

Separately and earlier, tens of thousands of personal-injury claims alleged Zyprexa’s hyperglycemia, diabetes and weight-gain risks were inadequately disclosed. Those claims settled confidentially in 2005–2007 for widely reported totals around $1.2 billion [2]. No court adjudicated causation — the settlements decided nothing except that both sides preferred certainty, and this page reports the figures as reported rather than as findings. Secondary sources routinely blend the two tracks into one scandal number; keeping them apart is most of what makes this page worth reading.

The metabolic effect itself needs no lawsuit: significant weight gain and metabolic changes are on the FDA label, and olanzapine sits at or near the top of antipsychotic comparisons for weight gain. The label, the real-world reports, and the prescription volume are on our olanzapine page, caveats first.

What is not in the record

• No Class I recall. Twenty recall records, all Class II or III, for manufacturing and quality problems [3].
• No adjudicated causation finding on the diabetes and weight claims — settled confidentially, decided by no one [2].
• No felony. The criminal plea was a misdemeanor [1]; pages that imply otherwise are rounding up.

What this means if you take olanzapine

Nothing here is a reason to change a dose on your own — for an antipsychotic, abrupt stopping carries some of the highest stakes in psychiatry. What two decades of litigation reduce to, practically, is one monitoring conversation the record says was historically under-had: “are we tracking weight, glucose and lipids, and what is the plan if they move?” If that monitoring is already happening, this page changes nothing. If it is not, it just did.

Common questions

What did Eli Lilly plead guilty to over Zyprexa?

A misdemeanor violation of the Food, Drug and Cosmetic Act: misbranding, for promoting Zyprexa as a treatment for dementia — including Alzheimer’s — in elderly patients, a use the FDA never approved. The January 2009 resolution totaled $1.415 billion, including a $515 million criminal fine that the DOJ described as the largest criminal fine ever imposed on an individual corporation in any US prosecution at that time.

What about the Zyprexa diabetes lawsuits?

A separate, earlier track: tens of thousands of personal-injury claims alleging inadequate warning about hyperglycemia, diabetes and severe weight gain were settled confidentially in 2005–2007, with widely reported totals around $1.2 billion. Those settlements adjudicated nothing — no court ruled on causation — and this page reports the figures as reported, not as findings.

Is the metabolic risk itself real?

Yes — independent of any lawsuit. Significant weight gain and metabolic effects are on the FDA label and rank among the best-documented adverse effects in psychiatry; olanzapine sits at or near the top of antipsychotic comparisons for weight gain. The litigation was about disclosure; the effect itself is label fact.

Has olanzapine had serious recalls?

No Class I recall — FDA’s most serious category — appears in the openFDA enforcement database. Twenty records exist, all Class II or III, nineteen terminated, for manufacturing and quality issues.

Does this mean I should stop taking olanzapine?

No — and for an antipsychotic the stakes of abrupt stopping are among the highest in psychiatry. The record here is about marketing conduct from two decades ago and confidential settlements; the useful question it hands you is concrete and current: "are we monitoring weight, glucose and lipids, and what is the plan if they move?"

Sources

Last verified 2026-08-31. Corrections change this date.